Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
304.2 GBX | -1.87% | +4.90% | +7.49% |
26/04 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
26/04 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.49% | 3.31B | |
+29.68% | 681B | |
+20.37% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+14.36% | 235B | |
+4.31% | 199B | |
-11.74% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Hutchmed to Present Cancer Drug Clinical Data at US Hematology Conference